How to buy Galmed Pharmaceuticals stock - 02 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Galmed Pharmaceuticals stock

Own Galmed Pharmaceuticals stock in just a few minutes.

Fact checked

Galmed Pharmaceuticals Ltd is a biotechnology business based in the US. Galmed Pharmaceuticals shares (GLMD) are listed on the NASDAQ and all prices are listed in US Dollars. Galmed Pharmaceuticals employs 17 staff and has a market cap (total outstanding shares value) of USD$86.8 million.

How to buy shares in Galmed Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Galmed Pharmaceuticals. Find the stock by name or ticker symbol: GLMD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Galmed Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Galmed Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Galmed Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Galmed Pharmaceuticals share price

Use our graph to track the performance of GLMD stocks over time.

Galmed Pharmaceuticals shares at a glance

Information last updated 2021-02-24.
52-week rangeUSD$2.96 - USD$6.2
50-day moving average USD$4.0324
200-day moving average USD$3.8453
Wall St. target priceUSD$17.8
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.585

Buy Galmed Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Galmed Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Galmed Pharmaceuticals financials

Gross profit TTM USD$0
Return on assets TTM -25.21%
Return on equity TTM -40.86%
Profit margin 0%
Book value $2.518
Market capitalisation USD$86.8 million

TTM: trailing 12 months

Shorting Galmed Pharmaceuticals shares

There are currently 37,745 Galmed Pharmaceuticals shares held short by investors – that's known as Galmed Pharmaceuticals's "short interest". This figure is 49.1% up from 25,317 last month.

There are a few different ways that this level of interest in shorting Galmed Pharmaceuticals shares can be evaluated.

Galmed Pharmaceuticals's "short interest ratio" (SIR)

Galmed Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Galmed Pharmaceuticals shares currently shorted divided by the average quantity of Galmed Pharmaceuticals shares traded daily (recently around 157270.83333333). Galmed Pharmaceuticals's SIR currently stands at 0.24. In other words for every 100,000 Galmed Pharmaceuticals shares traded daily on the market, roughly 240 shares are currently held short.

However Galmed Pharmaceuticals's short interest can also be evaluated against the total number of Galmed Pharmaceuticals shares, or, against the total number of tradable Galmed Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Galmed Pharmaceuticals's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Galmed Pharmaceuticals shares in existence, roughly 0 shares are currently held short) or 0.0021% of the tradable shares (for every 100,000 tradable Galmed Pharmaceuticals shares, roughly 2 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Galmed Pharmaceuticals.

Find out more about how you can short Galmed Pharmaceuticals stock.

Galmed Pharmaceuticals share dividends

We're not expecting Galmed Pharmaceuticals to pay a dividend over the next 12 months.

Galmed Pharmaceuticals share price volatility

Over the last 12 months, Galmed Pharmaceuticals's shares have ranged in value from as little as $2.96 up to $6.2. A popular way to gauge a stock's volatility is its "beta".

GLMD.US volatility(beta: 2.21)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galmed Pharmaceuticals's is 2.206. This would suggest that Galmed Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Galmed Pharmaceuticals overview

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in ARREST Phase III pivotal study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity, and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; and a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol. The company was founded in 2000 and is headquartered in Tel Aviv-Yafo, Israel.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site